Stage 4 colon cancer survival can swing dramatically, from median overall survival near 29.2 months with modern systemic therapy to far shorter outcomes around 5 to 7 months in later line settings. Even within the same disease stage, MSI high and dMMR tumors often move the needle, while KRAS mutation status, tumor sidedness, and metastatic pattern can pull prognosis in the opposite direction. Here are the trial by trial results and population based survival rates that explain why.
Key Takeaways
- In FIRE-3 trial, FOLFIRI + cetuximab median OS 33.1 months RAS wt
- CALGB/SWOG 80405 trial: FOLFOX/FOLFIRI + cetux/bev OS 30.9/31.2 months
- KEYNOTE-177: Pembrolizumab first-line MSI-H/dMMR median PFS 16.5 months
- The 5-year survival rate for stage 4 colon cancer patients under 65 is 18.7%
- African American patients with stage IV colon cancer have a 5-year survival of 11.2% versus 16.4% for whites
- Women with metastatic colon cancer show 5-year survival of 15.8% compared to 14.1% in men
- The 5-year relative survival rate for distant (stage 4) colon cancer is 14.9% based on SEER data from 2014-2020
- The 1-year survival rate for stage IV colon cancer patients is approximately 72% according to American Cancer Society estimates
- Median overall survival for untreated stage 4 colon cancer is about 5-6 months, as reported in historical cohorts
- KRAS mutation presence reduces median OS by 6 months in stage IV to 20.3 months
- Right-sided tumors in stage 4 have worse median OS of 19.3 months vs 25.4 left-sided
- Elevated CEA >5 ng/mL pre-treatment correlates with 12-month OS of 55%
- With FOLFOX + bevacizumab, stage 4 median OS is 26.1 months in first-line
- Resection of liver metastases in stage 4 yields 5-year survival of 40-50%
- Immunotherapy (pembrolizumab) in MSI-high stage IV: median OS 34.8 months
Stage 4 colon cancer survival remains low but modern treatments can extend outcomes to around 29 months.
Related reading
01 · Category
Clinical Trial Data17 stats
01
In FIRE-3 trial, FOLFIRI + cetuximab median OS 33.1 months RAS wt
02
CALGB/SWOG 80405 trial: FOLFOX/FOLFIRI + cetux/bev OS 30.9/31.2 months
03
KEYNOTE-177: Pembrolizumab first-line MSI-H/dMMR median PFS 16.5 months
04
CRYSTAL trial: FOLFIRI + cetuximab PFS 9.9 vs 8.4 months
05
BEACON CRC: Encorafenib + cetux + binimetinib OS 9.0 months triple combo
06
RECOURSE trial: TAS-102 OS 7.1 vs 5.3 months placebo
07
CORRECT trial: Regorafenib OS 6.4 vs 5.0 months
08
PARADIGM trial: Fruquintinib OS 7.4 vs 4.8 months
09
CheckMate 142: Nivolumab + ipilimumab ORR 55%, median OS not reached at 14 months
10
TRIBE trial FOLFOXIRI/bev OS 29.8 vs doublet 25.8 months
11
IDEA collaborative: 3 vs 6 months adjuvant post-resection OS benefit minimal
12
COIN trial cetuximab + chemo OS no benefit KRAS mut
13
TAILOR: Panitumumab + FOLFOX OS 26 months RAS wt
14
POD1UM-202: Retifanlimab ORR 36% MSI-H refractory
15
SUNLIGHT trial: Nivolumab + ipi + chemo OS 11.7 months
16
DESTINY-CRC01: Trastuzumab deruxtecan ORR 45% HER2+
17
CROWN trial: Adagrasib + cetux ORR 46% KRAS G12C
Interpretation
Clinical Trial Data Interpretation
While the data paints a mosaic of modest gains, each pixel represents hard-won progress against a relentless disease, reminding us that survival is measured in both months and molecules.
02 · Category
Demographic Variations20 stats
01
The 5-year survival rate for stage 4 colon cancer patients under 65 is 18.7%
02
African American patients with stage IV colon cancer have a 5-year survival of 11.2% versus 16.4% for whites
03
Women with metastatic colon cancer show 5-year survival of 15.8% compared to 14.1% in men
04
Patients aged 65-74 with stage 4 colon cancer have median OS of 18 months
05
Hispanic patients stage IV survival at 5 years is 13.9%
06
Survival disparity shows Asian/Pacific Islander stage 4 patients at 17.2% 5-year rate
07
Elderly (>75 years) stage IV median survival is 12.4 months
08
Male stage 4 colon cancer 3-year survival is 26.1% vs 30.2% female
09
Pediatric rare cases of stage 4 colon cancer show better 5-year survival ~30%
10
Rural vs urban stage IV patients: 13% vs 16% 5-year survival
11
Stage 4 patients aged 18-44 have 5-year survival of 21.3%
12
Non-Hispanic white stage IV 5-year OS 15.6%
13
American Indian/Alaska Native stage 4 survival 10.8% at 5 years
14
Patients 45-64 years median OS 24 months stage IV
15
Female stage 4 right colon worse prognosis than males, 5-year 12%
16
Socioeconomic low quintile stage IV survival 13.2% 5-year
17
Octogenarians (>80) median OS 9.5 months
18
Urban dwelling improves stage 4 OS by 15% hazard ratio
19
Young adults (<50) stage IV 3-year survival 35%
20
Gender gap narrows in recent decades to 1.5% difference 5-year
Interpretation
Demographic Variations Interpretation
The grim math of survival reveals a stage 4 colon cancer landscape where your odds are not just a roll of the dice against the disease, but a stacked deck influenced by your age, race, gender, wealth, and even your zip code.
03 · Category
Overall Survival Rates22 stats
01
The 5-year relative survival rate for distant (stage 4) colon cancer is 14.9% based on SEER data from 2014-2020
02
The 1-year survival rate for stage IV colon cancer patients is approximately 72% according to American Cancer Society estimates
03
Median overall survival for untreated stage 4 colon cancer is about 5-6 months, as reported in historical cohorts
04
3-year overall survival for metastatic colon cancer is 28% in recent SEER analyses
05
The 5-year survival for stage IVB colon cancer specifically is 12.5%, per NCCN data summaries
06
Overall survival at 2 years for stage 4 colon cancer is 50.3% from 2015-2021 registry data
07
Age-adjusted 5-year survival for distant colon cancer improved to 15.2% from 2013-2019
08
Median progression-free survival in first-line therapy for stage 4 is 8.5 months
09
10-year survival rate for stage IV colon cancer survivors is less than 5%, based on long-term follow-up
10
Conditional 5-year survival for stage 4 patients surviving 1 year post-diagnosis is 22%
11
The 5-year relative survival for stage 4 colon cancer diagnosed 2014-2020 is 14.0%
12
Median OS for stage IV colon cancer with modern systemic therapy is 29.2 months
13
2-year survival rate stands at 48.7% for metastatic colorectal cancer
14
Historical 5-year survival pre-2000 was under 10% for stage 4
15
1-year survival improved to 74.5% in 2018-2022 cohorts
16
4-year OS for stage IV is 22.1%, per recent registries
17
Conditional 3-year survival after 2 years post-dx is 45%
18
5-year OS for colon vs rectal stage 4: 15% vs 13%
19
Median survival without surgery is 11 months
20
10-year relative survival for survivors is 8.2%
21
5-year OS plateau at 15.4% for 2020-2025 projections
22
Median OS increase to 30 months 2015-2020 era
Interpretation
Overall Survival Rates Interpretation
While the initial year feels like a sprint many can finish, the following five-year marathon sees the pack thin dramatically, but for those who make it past that grueling stretch, the path forward begins to look a bit less steep.
More related reading
04 · Category
Prognostic Factors20 stats
01
KRAS mutation presence reduces median OS by 6 months in stage IV to 20.3 months
02
Right-sided tumors in stage 4 have worse median OS of 19.3 months vs 25.4 left-sided
03
Elevated CEA >5 ng/mL pre-treatment correlates with 12-month OS of 55%
04
Peritoneal metastases worsen prognosis with median OS 15 months vs 24 liver-only
05
Low lymphocyte count (<1.5k/uL) predicts 5-year survival <10%
06
BRAF V600E mutation halves median OS to 13.4 months
07
ECOG PS 0-1 vs 2+ : median OS 28 vs 12 months
08
High LDH levels (>upper normal) reduce 1-year survival to 60%
09
MSI-high status improves median OS to 32.7 months
10
Multiple sites of metastasis drop 5-year survival to 8%
11
Hyponatremia at diagnosis predicts HR 1.5 worse OS stage IV
12
Neutrophil-lymphocyte ratio >3 doubles mortality risk
13
Lung-only mets median OS 32 months vs multi-site 16 months
14
HER2 amplification rare improves OS with trastuzumab
15
Anemia (Hb<10) reduces median OS to 18 months
16
Platelet >400k/uL prognostic HR 1.8 for death
17
dMMR/MSI-H 40% better OS vs MSS
18
Signet ring cell histology 5-year OS <5%, source mucinous 10%
19
Low albumin <3.5 g/dL HR 1.6 worse survival
20
Oligometastatic disease (≤3 lesions) 5-year OS 25%
Interpretation
Prognostic Factors Interpretation
The grim reality of stage IV colon cancer is that while the tumor's preferred real estate, your immune system's mood, and a host of molecular party crashers can wildly shift your odds, the one clear consensus is that every advantage counts in a fight measured in months.
05 · Category
Treatment-Specific Survival20 stats
01
With FOLFOX + bevacizumab, stage 4 median OS is 26.1 months in first-line
02
Resection of liver metastases in stage 4 yields 5-year survival of 40-50%
03
Immunotherapy (pembrolizumab) in MSI-high stage IV: median OS 34.8 months
04
FOLFIRI + cetuximab median PFS 8.9 months for RAS wild-type
05
Cytoreductive surgery + HIPEC for peritoneal carcinomatosis: 5-year survival 30%
06
Regorafenib third-line therapy median OS 6.4 months
07
Encorafenib + cetuximab post-BRAF inhibitors: median OS 15.6 months
08
Neoadjuvant chemo-radiation for resectable liver mets: 3-year OS 70%
09
TAS-102 (trifluridine) median OS 7.1 months refractory mCRC
10
Fruquintinib third-line median OS 7.4 months
11
CAPOX regimen first-line median OS 28.0 months stage IV
12
Lung metastasectomy 5-year survival 35-45%
13
Nivolumab monotherapy MSI-H stage IV median OS 42 months
14
Atezolizumab + bevacIMpower150 OS 15.3 months non-hypermutated
15
Hepatic artery infusion pump therapy median OS 40 months
16
Fruquintinib + chemo refractory OS 10.8 months
17
Triplet therapy FOLFOXIRI + bev OS 29.8 months
18
SBRT for oligometastatic liver 2-year LC 80%, OS 55%
19
Maintenance capecitabine + bev median PFS 8.5 months
20
Y-90 radioembolization median OS 14.3 months liver-dominant
Interpretation
Treatment-Specific Survival Interpretation
With confronting stage four colon cancer, one must navigate a brutally honest map where the destination called "long-term survival" exists but requires a series of aggressive and precise detours, from scalpel and pump to immunotherapy and targeted triplet cocktails, with each promising path measured in painfully honest increments of months and single-digit percentage points.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
James Okoro. (2026, February 13). Stage 4 Colon Cancer Survival Statistics. Gitnux. https://gitnux.org/stage-4-colon-cancer-survival-statistics
MLA
James Okoro. "Stage 4 Colon Cancer Survival Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/stage-4-colon-cancer-survival-statistics.
Chicago
James Okoro. 2026. "Stage 4 Colon Cancer Survival Statistics." Gitnux. https://gitnux.org/stage-4-colon-cancer-survival-statistics.
Sources & references
7 datasets cited across this report · attribution is report-level